Related references
Note: Only part of the references are listed.The United Nations and the Urgent Need for Coordinated Global Action in the Fight Against Antimicrobial Resistance
Helen W. Boucher et al.
ANNALS OF INTERNAL MEDICINE (2016)
Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
Shashikant Srivastava et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Escherichia coli Harboring mcr-1 and blaCTX-M on a Novel IncF Plasmid: First Report of mcr-1 in the United States
Patrick McGann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks
Anthony McDonnell et al.
CLINICAL INFECTIOUS DISEASES (2016)
Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America
Tamar F. Barlam et al.
CLINICAL INFECTIOUS DISEASES (2016)
Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients
Francesca Mattioli et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Infectious Disease Expert Sees Threat From Colistin-Resistant Superbug
Jennifer Abbasi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Optimal Usage of Colistin: Are We Any Closer?
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2015)
Antibacterial Drug Development: Challenges, Recent Developments, and Future Considerations
S. Nambiar et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Guidance for the Knowledge and Skills Required for Antimicrobial Stewardship Leaders
Sara E. Cosgrove et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2014)
Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model
Brian VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Impact of Meropenem in Combination with Tobramycin in a Murine Model of Pseudomonas aeruginosa Pneumonia
Arnold Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Better Tests, Better Care: Improved Diagnostics for Infectious Diseases
Angela M. Caliendo et al.
CLINICAL INFECTIOUS DISEASES (2013)
A comprehensive regulatory framework to address the unmet need for new antibacterial treatments
John H. Rex et al.
LANCET INFECTIOUS DISEASES (2013)
White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens
Brad Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2012)
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Pranita D. Tamma et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia
T. P. Lodise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap!
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2010)
Reproducible Science
Arturo Casadevall et al.
INFECTION AND IMMUNITY (2010)
Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole
Keith A. Rodvold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Use of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community-Acquired Pneumonia: Implications for Future Clinical Trial Study Design
Paul G. Ambrose
CLINICAL INFECTIOUS DISEASES (2008)
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model
Paul G. Ambrose et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations
D Andes et al.
CLINICAL MICROBIOLOGY AND INFECTION (2005)
Use of pharmacokinetic-pharmaco dynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem
SM Bhavnani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Bacterial-population responses to drug-selective pressure:: Examination of garenoxacin's effect on Pseudomonas aeruginosa
VH Tam et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'
GL Drusano
NATURE REVIEWS MICROBIOLOGY (2004)
Randomized controlled trials
HO Stolberg et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2004)
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy
N Jumbe et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach
M Fava et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2003)
Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint
GL Drusano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
